58 results  1 of 3 

1 Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
Byung Wan Lee, KyungWan Min, Eun-Gyoung Hong, Bon Jeong Ku, Jun Goo Kang, Suk Chon, Won-Young Lee, Mi Kyoung Park, Jae Hyeon Kim, Sang Yong Kim, Keeho Song, Soon Jib Yoo
Endocrinol Metab.2023;38(3):328-337.   Published online 2023 June 28     DOI: http://dx.doi.org/10.3803/EnM.2023.1688
      
2 Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Tzu-Yi Lin, Eugene Yu-Chuan Kang, Shih-Chieh Shao, Edward Chia-Cheng Lai, Sunir J. Garg, Kuan-Jen Chen, Je-Ho Kang, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang
Diabetes Metab J.2023;47(3):394-404.   Published online 2023 March 6     DOI: http://dx.doi.org/10.4093/dmj.2022.0221
      
3 Effect of the addition of thiazolidinedione to sodium-glucose cotransporter 2 inhibitor therapy on lipid levels in type 2 diabetes mellitus: a retrospective study using Korean National Health Insurance Service data
Taegyun Park, Kyungdo Han, Dongwook Shin, Jongho Park
Cardiovasc Prev Pharmacother.2022;4(3):114-122.   Published online 2022 July 29     DOI: http://dx.doi.org/10.36011/cpp.2022.4.e15
      
4 Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
Nam Hoon Kim, Nan Hee Kim
Diabetes Metab J.2022;46(4):543-551.   Published online 2022 July 27     DOI: http://dx.doi.org/10.4093/dmj.2022.0209
      
5 Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
Diabetes Metab J.2023;47(1):82-91.   Published online 2022 June 20     DOI: http://dx.doi.org/10.4093/dmj.2021.0356
      
6 Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
Jong Ha Baek, Ye Seul Yang, Seung-Hyun Ko, Kyung Do Han, Jae Hyeon Kim, Min Kyong Moon, Jong Suk Park, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Jong Han Choi, Kyu Yeon Hur
Diabetes Metab J.2022;46(5):701-712.   Published online 2022 June 3     DOI: http://dx.doi.org/10.4093/dmj.2022.0002
      
7 Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
Seung Eun Lee, Hyewon Nam, Han Seok Choi, Hoseob Kim, Dae-Sung Kyoung, Kyoung-Ah Kim
Diabetes Metab J.2022;46(4):567-577.   Published online 2022 February 8     DOI: http://dx.doi.org/10.4093/dmj.2021.0160
      
8 Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
Dong Yoon Kang, Hyunah Kim, SooJeong Ko, HyungMin Kim, Jiwon Shinn, Min-Gyu Kang, Sun-ju Byeon, Jeong-Hee Choi, Soo-Yong Shin, Hun-Sung Kim
J Korean Med Sci.2022;37(7):e53.  Published online 2022 February 3     DOI: http://dx.doi.org/10.3346/jkms.2022.37.e53
      
9 Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee
Diabetes Metab J.2022;46(4):658-662.   Published online 2021 November 8     DOI: http://dx.doi.org/10.4093/dmj.2021.0232
      
10 Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
Jeonghoon Ha, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Seung Hyun Ko, Moo Il Kang, Sung Dae Moon, Ki-Hyun Baek
Endocrinol Metab.2021;36(4):895-903.   Published online 2021 August 9     DOI: http://dx.doi.org/10.3803/EnM.2021.1026
      
11 Cardamonin exerts a protective effect against autophagy and apoptosis in the testicles of diabetic male rats through the expression of Nrf2 via p62-mediated Keap-1 degradation
Shereen M. Samir, Mahmoud Elalfy, Eman Mohamad El Nashar, Mansour A. Alghamdi, Eman Hamza, Mohamed Saad Serria, Mona G. Elhadidy
Korean J Physiol Pharmacol.2021;25(4):341-354.   Published online 2021 July 1     DOI: http://dx.doi.org/10.4196/kjpp.2021.25.4.341
      
12 Cardiorenal Protection in Diabetic Kidney Disease
Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney
Endocrinol Metab.2021;36(2):256-269.   Published online 2021 April 19     DOI: http://dx.doi.org/10.3803/EnM.2021.987
      
13 Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinol Metab.2021;36(2):388-400.   Published online 2021 March 31     DOI: http://dx.doi.org/10.3803/EnM.2020.912
      
14 Far-infrared rays enhance mitochondrial biogenesis and GLUT3 expression under low glucose conditions in rat skeletal muscle cells
Yelim Seo, Young-Won Kim, Donghee Lee, Donghyeon Kim, Kyoungseo Kim, Taewoo Kim, Changyeob Baek, Yerim Lee, Junhyeok Lee, Hosung Lee, Geonwoo Jang, Wonyeong Jeong, Junho Choi, Doegeun Hwang, Jung Soo Suh, Sun-Woo Kim, Hyoung Kyu Kim, Jin Han, Hyoweon Bang, Jung-Ha Kim, Tong Zhou, Jae-Hong Ko
Korean J Physiol Pharmacol.2021;25(2):167-175.   Published online 2021 March 1     DOI: http://dx.doi.org/10.4196/kjpp.2021.25.2.167
      
15 Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Eun-Jung Rhee, Mee-Kyung Kim, Won-Young Lee
Endocrinol Metab.2021;36(1):41-50.   Published online 2021 February 24     DOI: http://dx.doi.org/10.3803/EnM.2021.106
      
16 Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
Ji-Yeon Lee, Minyoung Lee, Ji Young Lee, Jaehyun Bae, Eugene Shin, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
Diabetes Metab J.2021;45(6):921-932.   Published online 2021 February 22     DOI: http://dx.doi.org/10.4093/dmj.2020.0187
      
17 Treatment of Diabetic Kidney Disease: Current and Future
Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku
Diabetes Metab J.2021;45(1):11-26.   Published online 2021 January 22     DOI: http://dx.doi.org/10.4093/dmj.2020.0217
      
18 Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
Soo Yong Lee, Tae Wook Lee, Gyu Tae Park, Jae Ho Kim, Hyun-Chae Lee, Jung-Hwa Han, Aeseon Yoon, Dahye Yoon, Shukmann Kim, Soon Myung Jung, Jin Hee Choi, Min Ku Chon, Sang Hyun Lee, Ki Won Hwang, Jeongsu Kim, Yong Hyun Park, June Hong Kim, Kook Jin Chun, Jin Hur
Korean Circ J.2020;51(3):251-262.   Published online 2020 December 17     DOI: http://dx.doi.org/10.4070/kcj.2020.0303
      
19 Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim
Diabetes Metab J.2021;45(4):505-514.   Published online 2020 October 30     DOI: http://dx.doi.org/10.4093/dmj.2020.0057
      
20 Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon, ,
Diabetes Metab J.2020;44(4):489-497.   Published online 2020 August 21     DOI: http://dx.doi.org/10.4093/dmj.2020.0172
      

 1 of 3